Chronic liver disease: current concepts of disease mechanisms

被引:29
作者
Center, SA [1 ]
机构
[1] Cornell Univ, Coll Vet Med, Dept Internal Med, Ithaca, NY 14853 USA
关键词
D O I
10.1111/j.1748-5827.1999.tb03050.x
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 [兽医学];
摘要
Optimal management of chronic liver disease requires an understanding of aetiological factors or conditions initiating and sustaining tissue damage. Injury may derive initially from toxin or xenobiotic exposure (direct, biotransformation adducts, hypersensitivity responses or immune-mediated mechanisms), infectious organisms, inborn errors of metabolism, or pathological accumulations of transition metals (iron or copper), endotoxins or membranocytolytic bile acids. Secondarily, cells and mediators associated with inflammation, pathological expression of major histocompatibility foci on hepatocytes and biliary epithelia, aberrant initiation of apoptosis, modification of the extracellular matrix, and depletion of natural antioxidants can each play pivotal roles. Cholestatic liver injury derived from extrahepatic mechanical obstruction or intrahepatic cholestasis (many causes) can induce membrane damage subsequent to accumulation of membranocytolytic bile acids, copper retention, and membrane peroxidation. This paper reviews contemporary issues of chronic hepatocellular injury and hepatic fibrosis with the aim of broadening the clinical perspective of treatment strategies.
引用
收藏
页码:106 / 114
页数:9
相关论文
共 41 条
[1]
Alpini Gianfranco, 1994, P623
[2]
CIRCULATING AUTOANTIBODIES IN DOGS WITH CHRONIC LIVER-DISEASE [J].
ANDERSSON, M ;
SEVELIUS, E .
JOURNAL OF SMALL ANIMAL PRACTICE, 1992, 33 (08) :389-394
[3]
IMMUNOGENICITY OF RAT HEPATOCYTES IN-VIVO - EFFECT OF CHOLESTASIS-INDUCED CHANGES IN MAJOR HISTOCOMPATIBILITY COMPLEX EXPRESSION [J].
ARVIEUX, C ;
CALMUS, Y ;
GANE, P ;
LEGENDRE, C ;
MARIANI, P ;
DELELO, R ;
POUPON, R ;
NORDLINGER, B .
JOURNAL OF HEPATOLOGY, 1993, 18 (03) :335-341
[4]
BACON BR, 1996, HEPATOLOGY TXB LIVER, P1439
[5]
SUBCELLULAR CHANGES AND APOPTOSIS INDUCED BY ETHANOL IN RAT-LIVER [J].
BENEDETTI, A ;
BRUNELLI, E ;
RISICATO, R ;
CILLUFFO, T ;
JEZEQUEL, AM ;
ORLANDI, F .
JOURNAL OF HEPATOLOGY, 1988, 6 (02) :137-143
[6]
BISSELL MD, 1996, HEPATOLOGY TXB LIVER, P506
[7]
CZAJA AJ, 1996, HEPATOLOGY TXB LIVER, P1259
[8]
EXPRESSION OF CLASS-I AND CLASS-II MAJOR HISTOCOMPATIBILITY COMPLEX ANTIGENS ON HUMAN HEPATOCYTES [J].
FRANCO, A ;
BARNABA, V ;
NATALI, P ;
BALSANO, C ;
MUSCA, A ;
BALSANO, F .
HEPATOLOGY, 1988, 8 (03) :449-454
[9]
Molecular mechanisms of hepatic fibrosis and principles of therapy [J].
Friedman, SL .
JOURNAL OF GASTROENTEROLOGY, 1997, 32 (03) :424-430
[10]
GHISHAN FK, 1996, HEPATOLOGY TXB LIVER, P1565